| NCT ID | NCT05439863 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Condition | Aortic Valve Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2022-07-01 |
| Primary Completion | 2032-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2022-07-01 with a primary completion date of 2032-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surgical aortic valve replacement (SAVR). However, many different issues have emerged: TAVR in younger patients? valve leaflet thrombosis? transcatheter valve durability? coronary reaccess after TAVR? TAVR in bicuspid aortic valve? TAVR in aortic regurgitation? etc. Hence, a prospective, multicenter database is created to provide the real-word data for these questions.
Eligibility Criteria
Inclusion Criteria: 1. Clinical diagnosis of severe aortic stenosis or aortic regurgitation 2. Patients undergo transcatheter aortic valve replacement Exclusion Criteria: patients refuse the clinical follow-up
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05439863 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Aortic Valve Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05439863 currently recruiting?
Yes, NCT05439863 is actively recruiting participants. Contact the research team at jameszll@163.com for enrollment information.
Where is the NCT05439863 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT05439863 clinical trial?
NCT05439863 is sponsored by Nanjing First Hospital, Nanjing Medical University. The trial plans to enroll 5,000 participants.